18. MDR-TB management: new approaches
Friday, 31 October 2014, 12:45-14:15

Chairs: Lucy Chesire (Kenya), John Watson (UK)  Section: Tuberculosis

OAP-336-31  Resistance to ethambutol, pyrazinamide, streptomycin and second-line drugs amongst MTB strains susceptible to isoniazid and rifampicin by the MODS assay
12:45-12:55  A Mendoza, A Alarcon, E Castillo, A San Miguel, E Leo, L Asencios, N Quispe, D Moore (Peru, UK)

OAP-337-31  Association between regimen composition and sputum culture conversion in patients with multidrug-resistant tuberculosis
12:55-13:05  C Yuen, E Kurbatova, J Ershova, T Dalton, P Cegielski, and Global Petts Investigators (USA)

OAP-338-31  Mycobacterium tuberculosis resistance to bedaquiline
13:05-13:15  K Andries, C Villellas, N Coeck, N Lounis, B De Jong, A Kou (Belgium)

OAP-339-31  A single-tube single-color assay for all allelic variants of the first line gene targets inhA, katG and rpoB that cause MDR-TB
13:15-13:25  W Wangh, J Rice, K. Pierce, V Allerheiligen, M Eckart, D Hain (USA, Germany)

OAP-340-31  Treatment outcomes in a large cohort of patients with drug-resistant tuberculosis co-infected with the HIV

OAP-341-31  Dose-ranging activity of clofazimine in the mouse model of tuberculosis chemotherapy
13:35-13:45  D Almeida, N Ammerman, C Moodley, B Ncgobo, R Swanson, A Dorasamy, J Adamson, J Grosset (South Africa, USA)

OAP-342-31  The individual-tailored treatment regimens for multidrug-resistant tuberculosis
13:45-13:55  T Ivanushkina, S Borisov, N Litvinova (Russian Federation)

OAP-343-31  Association of previous treatment history with treatment outcome among patients with multidrug-resistant tuberculosis
13:55-14:05  P Cegielski, J Ershova, C Kvasnovsky, E Kurbatova, T Dalton, C C Contreras, J Campos Caoili, and Global Petts Investigators (USA, UK, Peru, Philippines)

14:05-14:15  Discussion